Hawaii 2024 Regular Session

Hawaii Senate Bill SCR36 Compare Versions

Only one version of the bill is available at this time.

Old	New	Differences
1	1	THE SENATE S.C.R. NO. 36 THIRTY-SECOND LEGISLATURE, 2024 STATE OF HAWAII SENATE CONCURRENT RESOLUTION requesting the Department of the Attorney General to conduct a study to determine if xylazine testing strips should be excluded from the STate's definition of drug paraphernalia.
2	2
3	3	THE SENATE S.C.R. NO. 36
4	4	THIRTY-SECOND LEGISLATURE, 2024
5	5	STATE OF HAWAII
6	6
7	7	THE SENATE
8	8
9	9	S.C.R. NO.
10	10
11	11	36
12	12
13	13	THIRTY-SECOND LEGISLATURE, 2024
14	14
15	15
16	16
17	17	STATE OF HAWAII
18	18
19	19
20	20
21	21
22	22
23	23
24	24
25	25
26	26
27	27
28	28
29	29	SENATE CONCURRENT
30	30
31	31	RESOLUTION
32	32
33	33
34	34
35	35
36	36
37	37	requesting the Department of the Attorney General to conduct a study to determine if xylazine testing strips should be excluded from the STate's definition of drug paraphernalia.
38	38
39	39
40	40
41	41
42	42
43	43
44	44
45	45	WHEREAS, xylazine is a non-opiate sedative, analgesic, and muscle relaxant that has been only approved by the United States Food and Drug Administration for veterinary use; and WHEREAS, xylazine has been increasingly identified as a cutting agent or adulterant in the illicit drug supply, often mixed with fentanyl, which increases the risk of a fatal drug overdose; and WHEREAS, as of November 2022, xylazine was found in the illicit drug supply in forty-eight of fifty states and is currently associated with one in ten fatal fentanyl overdoses; and WHEREAS, although symptoms of xylazine use and opioid use are similar, overdose reversal agents such as naloxone do not counteract the effects of xylazine; and WHEREAS, there is currently no drug approved by the Food and Drug Administration to reverse the effects of xylazine in humans; and WHEREAS, in 2023, multiple states considered legislation to schedule xylazine as a controlled substance; and WHEREAS, historically state drug paraphernalia laws have prohibited the possession of drug-checking equipment, such as fentanyl test strips, which can be used by a person who uses drugs to test their supply for an adulterated substance; and WHEREAS, in order to combat overdose deaths from drugs adulterated by fentanyl, legislatures across the country have altered their drug paraphernalia laws to either explicitly legalize fentanyl test strips or generally legalize drug-checking equipment; and WHEREAS, similar steps should be taken to combat the rise of drugs adulterated by xylazine; now, therefore, BE IT RESOLVED by the Senate of the Thirty-second Legislature of the State of Hawaii, Regular Session of 2024, the House of Representatives concurring, that the Department of the Attorney General is requested to conduct a study to determine if xylazine testing strips should be excluded from the State's definition of drug paraphernalia; and BE IT FURTHER RESOLVED that the Department of the Attorney General is requested to submit a report of its study, including findings and recommendations, and any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2025; and BE IT FURTHER RESOLVED that a certified copy of this Concurrent Resolution be transmitted to the Attorney General. OFFERED BY: _____________________________ Report Title: Xylazine Test Strips; Drug Paraphernalia; Study; Attorney General
46	46
47	47	WHEREAS, xylazine is a non-opiate sedative, analgesic, and muscle relaxant that has been only approved by the United States Food and Drug Administration for veterinary use; and
48	48
49	49
50	50
51	51	WHEREAS, xylazine has been increasingly identified as a cutting agent or adulterant in the illicit drug supply, often mixed with fentanyl, which increases the risk of a fatal drug overdose; and
52	52
53	53
54	54
55	55	WHEREAS, as of November 2022, xylazine was found in the illicit drug supply in forty-eight of fifty states and is currently associated with one in ten fatal fentanyl overdoses; and
56	56
57	57
58	58
59	59	WHEREAS, although symptoms of xylazine use and opioid use are similar, overdose reversal agents such as naloxone do not counteract the effects of xylazine; and
60	60
61	61
62	62
63	63	WHEREAS, there is currently no drug approved by the Food and Drug Administration to reverse the effects of xylazine in humans; and
64	64
65	65
66	66
67	67	WHEREAS, in 2023, multiple states considered legislation to schedule xylazine as a controlled substance; and
68	68
69	69
70	70
71	71	WHEREAS, historically state drug paraphernalia laws have prohibited the possession of drug-checking equipment, such as fentanyl test strips, which can be used by a person who uses drugs to test their supply for an adulterated substance; and
72	72
73	73
74	74
75	75	WHEREAS, in order to combat overdose deaths from drugs adulterated by fentanyl, legislatures across the country have altered their drug paraphernalia laws to either explicitly legalize fentanyl test strips or generally legalize drug-checking equipment; and
76	76
77	77
78	78
79	79	WHEREAS, similar steps should be taken to combat the rise of drugs adulterated by xylazine; now, therefore,
80	80
81	81
82	82
83	83	BE IT RESOLVED by the Senate of the Thirty-second Legislature of the State of Hawaii, Regular Session of 2024, the House of Representatives concurring, that the Department of the Attorney General is requested to conduct a study to determine if xylazine testing strips should be excluded from the State's definition of drug paraphernalia; and
84	84
85	85
86	86
87	87	BE IT FURTHER RESOLVED that the Department of the Attorney General is requested to submit a report of its study, including findings and recommendations, and any proposed legislation, to the Legislature no later than twenty days prior to the convening of the Regular Session of 2025; and
88	88
89	89
90	90
91	91	BE IT FURTHER RESOLVED that a certified copy of this Concurrent Resolution be transmitted to the Attorney General.
92	92
93	93
94	94
95	95
96	96
97	97
98	98
99	99	OFFERED BY: _____________________________
100	100
101	101
102	102
103	103	OFFERED BY:
104	104
105	105	_____________________________
106	106
107	107
108	108
109	109
110	110
111	111
112	112
113	113
114	114
115	115
116	116
117	117
118	118
119	119	Report Title:
120	120
121	121	Xylazine Test Strips; Drug Paraphernalia; Study; Attorney General